Edgar Filing: Aeterna Zentaris Inc.

FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

REPORT OF FOREIGN ISSUER

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of March, April and May 2004

AETERNA LABORATORIES INC.
-----------------------------------------------------
(Translation of registrant's name into English)

1405, boul. du Parc-Technologique
Quebec, Quebec
Canada, G1P 4P5
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F X
----- -----

Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934

Yes No X
----- -----

If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-
-----

DOCUMENTS INDEX

DOCUMENTS DESCRIPTION
--------- -----------
--------------------------------------------------------------------------------------------------------

1. Press release of March 22, 2004: AETERNA SUBSIDIARY ZENTARIS TO PRESENT
AT STOCK DAY SPRING 2004 CONFERENCE IN GERMANY

2. Press release of March 29, 2004: AETERNA ADOPTS SHAREHOLDER RIGHTS PLAN

3. Press release of March 31, 2004: AETERNA SUBSIDIARY ZENTARIS REPORTS
POSITIVE PRECLINICAL RESULTS FROM NOVEL PYRAZOLE COMPOUND

4. Press release of April 2, 2004: AETERNA SUBSIDIARY ZENTARIS SIGNS NEW
AGREEMENT WITH ARDANA BIOSCIENCE FOR LHRH ANTAGONIST TEVERELIX

5. Press release of April 7, 2004: AETERNA SUBSIDIARY ZENTARIS TO PRESENT
FINAL RESULTS FROM PHASE I TRIAL OF PERIFOSINE IN COMBINATION
WITH RADIOTHERAPY AT 2004 AMERICAN SOCIETY OF CLINICAL ONCOLOGY
(ASCO) ANNUAL MEETING

6. Press release of April 21, 2004: AETERNA SUBSIDIARY ZENTARIS
ANNOUNCES INITIATION OF DOSE RANGING STUDY FOR A NOVEL ORAL
AGENT THAT STIMULATES GROWTH HORMONE SECRETION

7. Press release of April 29, 2004: AETERNA/ZENTARIS AND SOLVAY REPORT
HEADLINE POSITIVE DATA FROM SIX PHASE II TRIALS OF CETRORELIX IN THREE
INDICATIONS: ENDOMETRIOSIS, UTERINE MYOMAS AND BENIGN PROSTATIC
HYPERPLASIA

8. Press release of May 4, 2004: AETERNA LABORATORIES REPORTS FIRST QUARTER
2004 FINANCIAL AND OPERATING RESULTS

9. Press release of May 11, 2004: AETERNA LABORATORIES TO HOLD
INVESTOR AND ANALYST DAY ON MAY 17, 2004 IN NEW YORK CITY
--------------------------------------------------------------------------------------------------------

DOCUMENTS DESCRIPTION
--------- -----------
--------------------------------------------------------------------------------------------------------

10. Press release of May 17, 2004: AETERNA/ZENTARIS TO PRESENT
DETAILED POSITIVE PHASE II DATA ON CETRORELIX AND NEW
PRECLINICAL DATA ON PERIFOSINE DURING INVESTOR AND ANALYST DAY
IN NEW YORK CITY

11. Press release of May 17, 2004: AETERNA LABORATORIES ADDED TO
NASDAQ BIOTECH INDEX

12. Press release of May 19, 2004: AETERNA TO PRESENT AT UBS GLOBAL
SPECIALTY PHARMACEUTICALS CONFERENCE MAY 24 AND ANNUAL
SHAREHOLDER MEETING TO BE HELD MAY 26

13. Press release of May 25, 2004: AETERNA/ZENTARIS TO PRESENT TODAY
ADDITIONAL DETAILED POSITIVE PHASE II DATA ON CETRORELIX IN
GYNECOLOGICAL INDICATIONS AT THE 18TH WORLD CONGRESS OF THE
INTERNATIONAL FEDERATION OF FERTILITY SOCIETIES (IFFS)

14. Press release of May 26, 2004: AETERNA LABORATORIES HOLDS 2004 ANNUAL
SHAREHOLDER MEETING AND ANNOUNCES COMPANY NAME CHANGE TO AETERNA ZENTARIS
--------------------------------------------------------------------------------------------------------

[AETERNA LOGO]

PRESS RELEASE
FOR IMMEDIATE RELEASE

AETERNA SUBSIDIARY ZENTARIS TO PRESENT AT
STOCK DAY SPRING 2004 CONFERENCE IN GERMANY

Innovative drugs form the basis for renewed business expansion

QUEBEC CITY, QUEBEC, MARCH 22, 2004 - Professor Dr Juergen Engel, Chairman and
Managing Director of Zentaris GmbH, a wholly-owned subsidiary of AEterna
Laboratories Inc. (TSX: AEL; Nasdaq: AELA) and Executive Vice President, Global
R&D, Chief Operating Officer at AEterna, will be presenting AEterna-Zentaris'
extensive product pipeline at the Stock Day Spring 2004 Conference on Wednesday,
March 24, 2004 at the Hilton Hotel in Frankfurt, Germany.

With regard to projects in clinical development, the Company with a focus on
oncology and endocrinology is making a special note of Cetrorelix and
Perifosine. Cetrorelix, for which a comprehensive licensing agreement with
Solvay Pharmaceuticals exists, is currently in 7 phase II clinical trials for
the indications of benign prostate enlargement (BPH), endometriosis and uterus
myoma. With Perifosine, for which the U.S. company Keryx Biopharmaceutical has
acquired the North American rights, Zentaris targets broad based applications in
oncology. In the fight against cancer, Perifosine has gained a great deal of
recognition among experts as the first oral AKT inhibitor. For both projects,
comprehensive Phase II programs were advanced or, respectively, started in 2003.
At the same time, Zentaris obtained very promising research results with early
projects from its in-house drug discovery unit. The Company thus considers
itself to be excellently positioned for the future as well.

Zentaris GmbH has once again significantly expanded its business in 2003. Based
on a revenue growth of approximately 36 percent to close to E30 million
(C$49 million), the biopharma company achieved a profit before interest and
taxes for the first time in its young history. Already in 2002, Zentaris was
able to finance ongoing operations with its own funds. In 2003 the company
continued this development in line with the progressing marketing of the
research projects, again generating a positive cash flow from operations.

"The financial figures, which significantly improved once again, show that we
are successfully advancing the innovative research and development projects of
our well filled pipeline as part of the AEterna-group," says professor Dr.
Juergen Engel, Chairman and Managing Director of Zentaris GmbH and Chief
Operating Officer of AEterna Laboratories Inc. He adds: "Next to the integration
of Zentaris into the AEterna-group, the extension of the agreement with Serono
International S.A., Zentaris' partner for the marketing of our product
Cetrotide(R), was of particular significance in fiscal year 2003. Cetrotide(R)
is used in the area of in vitro fertilization. In addition, we saw the market
introduction of Impavido(R), the first orally administered medication to fight
the deadly tropical disease leishmaniasis."

ABOUT AETERNA LABORATORIES

AEterna Laboratories Inc. along with its wholly-owned subsidiary Zentaris GmbH,
is a biopharmaceutical company with an extensive product portfolio, including
two marketed products and 14 other product candidates under development in
oncology, endocrinology and infectious diseases. Cetrorelix (Cetrotide(R)) is
sold in the U.S., Europe and several other countries to the IN VITRO
fertilization market, and is in Phase II clinical trials for endometriosis,
uterus myoma and enlarged prostate (BPH). Miltefosine (Impavido(R)) is sold for
black fever and has successfully completed a Phase III trial in parasitic skin
disease. Neovastat(R) is in a Phase III trial for non-small cell lung cancer.
Perifosine, the first orally-active AKT inhibitor, is in Phase II trials for
multiple cancers. Several other clinical programs are underway with various
potential development candidates, supported by a worldwide network of scientific
and marketing partnerships. Furthermore, AEterna benefits from a discovery
platform of 100,000 molecules, which is generating promising new compounds.

AEterna also owns 62% of its subsidiary Atrium Biotechnologies Inc. which
develops and markets active ingredients and speciality fine chemicals in the
health and personal care industry for the cosmetics, chemical, pharmaceutical
and nutritional industries. Its international business network and portfolio of
over 1,000 products sold to over 2,000 institutional customers and to over
36,000 physicians and other health care professionals, have generated
significant growth in sales and earnings since the Company was founded in
January 2000. In 2003, Atrium sales exceeded $120 million.

AEterna shares are listed on the Toronto Stock Exchange (AEL) and the NASDAQ
National Market (AELA). News releases and additional information about AEterna
are available on its Web site at www.aeterna.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements made pursuant to the safe
harbor provisions of the U.S. Securities Litigation Reform Act of 1995.
Forward-looking statements involve known and unknown risks and uncertainties,
which could cause the Company's actual results to differ materially from those
in the forward-looking statements. Such risks and uncertainties include, among
others, the availability of funds and resources to pursue R&D projects, the
successful and timely completion of clinical studies, the ability of the Company
to take advantage of business opportunities in the pharmaceutical industry,
uncertainties related to the regulatory process and general changes in economic
conditions. Investors should consult the Company's quarterly and annual filings
with the Canadian and U.S. securities commissions for additional information on
risks and uncertainties relating to the forward-looking statements. Investors
are cautioned not to rely on these forward-looking statements. The Company does
not undertake to update these forward-looking statements.

-30-

CONTACTS:

MEDIA RELATIONS INVESTOR RELATIONS

Paul Burroughs Jacques Raymond
(418) 652-8525 ext. 406 (418) 652-8525 ext. 360
paul.burroughs@aeterna.com Cell. : (514) 703-5654
-------------------------- jacques.raymond@aeterna.com
---------------------------

EUROPE
Dr. Mathias Pietras
+49(0) 69 42 602 3423
mathias.pietras@zentaris.de
---------------------------

[AETERNA LOGO]

PRESS RELEASE
FOR IMMEDIATE RELEASE

AETERNA ADOPTS SHAREHOLDER RIGHTS PLAN

QUEBEC CITY, QUEBEC, MARCH 29, 2004 - AEterna Laboratories Inc. (TSX: AEL;
Nasdaq: AELA) announced today that its Board of Directors has adopted a
shareholder rights plan (the "Rights Plan"), which takes effect immediately. The
objectives of the Rights Plan are to provide adequate time for the Corporation's
Board of Directors and shareholders to assess an unsolicited takeover bid for
the Corporation, to provide the Board of Directors with sufficient time to
explore and develop alternatives for maximizing shareholder value if a takeover
bid is made, and to provide shareholders with an equal opportunity to
participate in a takeover bid.

"This Rights Plan is similar to those adopted by other companies and approved by
their shareholders. Furthermore, AEterna's management and directors believe that
the Rights Plan preserves the fair treatment of all shareholders, is consistent
with Canadian corporate practices and addresses institutional investor
guidelines. AEterna is not adopting this Rights Plan in response to any specific
proposal to acquire control of the Corporation, nor is it aware of any such
intention," said Gilles Gagnon, President and Chief Executive Officer of
AEterna.

While the Rights Plan takes effect immediately, it is subject to regulatory
approval and to ratification by AEterna's shareholders at its annual general
meeting on May 26, 2004. The Rights Plan will be in effect for three (3) years,
with one renewal option, subject to shareholder approval. The rights issued to
the shareholders under the Rights Plan will be exercisable only when a person or
entity, including any related party(ies), acquires or announces its intention to
acquire more than twenty (20) percent of the outstanding subordinate voting
shares of AEterna (as such shares may be redesignated or reclassified) without
complying with the "permitted bid" provisions of the Rights Plan or without
approval of AEterna's Board of Directors. Should such an acquisition occur, each
right would, upon exercise, entitle a holder, other than the person pursuing the
acquisition together with its related party(ies), to purchase subordinate voting
shares of AEterna at a fifty (50) percent discount to the market price of
AEterna's shares at the time.

Under the Rights Plan, a permitted bid is one made to all shareholders that is
open for acceptance for not less than sixty (60) days. If at the end of such
sixty (60)-day period more than fifty (50) percent of the outstanding
subordinate voting shares of AEterna, other than those owned by the person or
entity pursuing the acquisition together with its related party(ies), have been
tendered, the person or entity pursuing the acquisition may take up and pay for
the shares but must extend the bid for a further ten (10) days to allow other
shareholders to tender. Under the permitted bid mechanism, shareholders will
have more time to consider the bid and any other options that may be available
before deciding whether

or not to tender their shares to the bid. The Board of Directors will also have
time to consider and pursue alternatives and to make recommendations to
shareholders.

ABOUT AETERNA LABORATORIES

FORWARD-LOOKING STATEMENTS

-30-

CONTACTS:

AETERNA LABORATORIES U.S. INVESTOR RELATIONS
MEDIA RELATIONS Lippert/Heilshorn & Associates
Paul Burroughs Kim Golodetz
(418) 652-8525 ext. 406 (212) 838-3777
paul.burroughs@aeterna.com kgolodetz@lahai.com

INVESTOR RELATIONS Bruce Voss
Jacques Raymond (310) 691-7100
(418) 652-8525 ext. 360 bvoss@lhai.com
Cell. : (514) 703-5654
jacques.raymond@aeterna.com

[AETERNA LOGO]

PRESS RELEASE
For immediate release

AETERNA SUBSIDIARY ZENTARIS REPORTS POSITIVE PRECLINICAL RESULTS FROM
NOVEL PYRAZOLE COMPOUND

Results indicate ZEN-014 as a new candidate
for the development of a potent anticancer drug

ORLANDO, FLORIDA (UNITED STATES), MARCH 31, 2004 - AEterna Laboratories Inc.
(TSX: AEL; Nasdaq: AELA) and its subsidiary Zentaris GmbH report that positive
preclinical results of their novel tubulin-inhibitor ZEN-014 were presented
earlier today at the American Association for Cancer Research (AACR) meeting in
Orlando, Florida.

ZEN-014 is a novel pyrazole derivative that was discovered by Zentaris. It
represents a new class of small molecule tubulin binders with antiangiogenic
properties which are assumed to be novel highly potent anticancer drugs with
blockbuster potential.

ZEN-014 inhibits tubulin polymerization with an IC50 of 1.3 uM. The treatment
with non-toxic concentrations (10 nM) of ZEN-014 inhibits endothelial cell
sprouting and vessel formation. Cancer cells (KB/HeLa) were arrested completely
in the G2M phase of mitosis at nanomolar concentrations (IC50: 34 nM) and
subsequently underwent apoptosis. Several apoptotic parameters as cell membrane
alterations, increase of caspase 3 and 7 activity, DNA fragmentation and
inactivation of the Bcl-2 protein are detectable in U937 cancer cells after
treatment with nanomolar concentrations of ZEN-014.

The compound shows an excellent antitumor activity profile in a broad panel of
tumor cell lines (average IC50 of 40 nM) including paclitaxel and vincristine
resistant cells. ZEN-014 exhibits promising in vivo activity in a renal cell
carcinoma model at a dose of 50 mg/kg after oral application.

"These excellent results again show the capability of our own drug discovery
unit which is the core for the continuous supply of new development candidates
and essential for the growth of our Company", said Prof. Dr. Jurgen Engel,
Executive Vice President, Global R&D and Chief Operating Officer at AEterna,
Chairman and Managing Director of Zentaris GmbH.

Based on these excellent IN VITRO and IN VIVO activities, ZEN-014 is a promising
new candidate for further preclinical development. ZEN-014 combines
antiproliferative activity at nanomolar concentrations with strong inhibition of
angiogenesis.

ABOUT AETERNA LABORATORIES

AEterna Laboratories Inc. along with its wholly-owned subsidiary Zentaris GmbH,
is a biopharmaceutical company with an extensive product portfolio, including
two marketed products and several other product candidates under development in
oncology, endocrinology and infectious diseases. Cetrotide(R) (Cetrorelix) is
sold in the U.S., Europe and several other countries to the IN VITRO
fertilization market, and is in Phase II clinical trials for endometriosis,
uterus myoma and enlarged prostate (BPH). Impavido(R) (Miltefosine) is sold for
black fever and has successfully completed a Phase III trial in parasitic skin
disease. Neovastat(R) is in a Phase III trial for non-small cell lung cancer.
Perifosine, the first orally-active AKT inhibitor, is in Phase II trials for
multiple cancers. Several other clinical programs are underway with various
potential development candidates, supported by a worldwide network of scientific
and marketing partnerships. Furthermore, AEterna benefits from a discovery
platform of 100,000 molecules, which is generating promising new compounds.

In addition, AEterna owns 62% of Atrium Biotechnologies Inc., which develops and
markets active ingredients and specialty chemicals in the health and personal
care industry for the cosmetics, pharmaceutical, chemical and nutritional
sectors. In 2003, Atrium sales exceeded $120 million.

FORWARD-LOOKING STATEMENTS

CONTACTS:

AETERNA LABORATORIES
MEDIA RELATIONS INVESTOR RELATIONS
Paul Burroughs Jacques Raymond
(418) 652-8525 ext. 406 (418) 652-8525 ext. 360
(418) 573-8982 cell. (514) 703-5654 cell.
paul.burroughs@aeterna.com jacques.raymond@aeterna.com

U.S. INVESTOR RELATIONS EUROPE
Lippert/Heilshorn & Associates Zentaris GmbH
Kim Golodetz Dr. Mathias Pietras
(212) 838-3777 phone: + 49 69 42 602 3423
kgolodetz@lhai.com fax: + 49 69 42 602 3444
Bruce Voss mathias.pietras@zentaris.de
(310) 691-7100 www.zentaris.com
bvoss@lhai.com

[AETERNA LOGO]

PRESS RELEASE
FOR IMMEDIATE RELEASE

AETERNA SUBSIDIARY ZENTARIS SIGNS NEW AGREEMENT WITH
ARDANA BIOSCIENCE FOR LHRH ANTAGONIST TEVERELIX

QUEBEC CITY, QUEBEC, APRIL 2, 2004 - AEterna Laboratories Inc. (TSX: AEL ;
NASDAQ: AELA) announced that its wholly owned subsidiary Zentaris GmbH and
Ardana Bioscience, a specialty pharmaceutical company, from Edinburgh, Scotland,
have signed a new agreement for the LHRH antagonist Teverelix. Ardana acquired
full global rights and is assigned the intellectual property relating to
Teverelix and the underlying microcrystalline suspension technology. In return,
Zentaris receives a substantial payment at signature, fixed annual guaranteed
payments until 2006, as well as potential future income on sales of Teverelix.

As part of the agreement, Zentaris will provide certain development services
and supply clinical samples to Ardana. Teverelix Phase I clinical trial
evaluating a sustained release formulation for use in prostate cancer is nearing
conclusion.

"We are delighted with the restructuring of the existing Teverelix collaboration
in place with our Scottish partner", says Professor Dr. Juergen Engel, Chairman
and Managing Director of Zentaris GmbH and Chief Operating Officer of AEterna.
"It emphasises the commitment of Ardana towards a successful development of
Teverelix. At the same time it allows for Zentaris to generate double-digit
million Euro risk-free income in the short and mid-term, while also potentially
profiting from a successful commercialisation of the product."

Dr Maureen Lindsay, Ardana Chief Operating Officer said, "We are delighted to
have secured all global rights to Teverelix, such that we can reap the full
benefits of its development and commercialization. Our strategy is to focus on
drugs prescribed by specialist clinicians, a market we can service effectively
with our planned specialist sales force. Teverelix fits neatly into this
strategy and is central to our burgeoning research and development portfolio,
which is on track to provide products that address five different indications in
Phase III clinical trials by the end of 2005."

Mr. Gilles Gagnon, President and Chief Executive Officer of AEterna Laboratories
Inc. added, "Ardana continues to be an important partner beyond Teverelix, also
holding the worldwide rights to our Growth Hormone Secretagogue (GHS), another
project from our promising pipeline. This significant transaction is a key step
in the building of our strategic portfolio."

ABOUT ARDANA BIOSCIENCE

Ardana Bioscience is a specialty pharmaceutical company focused on reproductive
health. It aims to become a leading source of clinical and commercial innovation
in the $20 billion human reproductive health market, which is growing at 9% per
annum. In addition to the androgen replacement therapy which will be launched in
the UK in 2004, Ardana has a rich development portfolio including Chronodyne(R)
(terbutaline) for endometriosis-related infertility (being developed in
collaboration with Columbia Laboratories (NASDAQ: CBRX) and LHRH analogs
Teverelix and 'Leuprorelin' for a wide variety of reproductive indications.
Ardana's therapeutic interests encompass androgen replacement, infertility,
sexual dysfunction and obstetrics.

Since its inception, Ardana has raised (pound)34.5 million in three funding
rounds. Ardana investors include Merlin Biosciences Limited, MVM Limited (MVM),
Techno Venture Management (TVM), ABN-AMRO Participates, 3i Group plc, ISIS
Equity Partners plc, Scottish Widows Investment Partnership Ltd, Mitsubishi
Corporation and Green Highlander, LLC. The company was created in July 2000 to
commercialise research by the Medical Research Council (MRC)'s Human
Reproductive Sciences Unit (HRSU) in Edinburgh, Scotland, which has been at the
forefront of this area of research for the last 30 years. The MRC employs nearly
100 staff at the Unit, which currently receives total annual funding of
(pound)3.8 million.

For more information on Ardana, consult www.ardana.co.uk

ABOUT AETERNA LABORATORIES

FORWARD-LOOKING STATEMENTS

-30-

CONTACTS:

[AETERNA LOGO]

PRESS RELEASE
FOR IMMEDIATE RELEASE

AETERNA SUBSIDIARY ZENTARIS TO PRESENT FINAL RESULTS FROM PHASE I TRIAL
OF PERIFOSINE IN COMBINATION WITH RADIOTHERAPY AT 2004 AMERICAN
SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING

QUEBEC CITY, QUEBEC, APRIL 7, 2004 - AEterna Laboratories Inc. (TSX: AEL;
Nasdaq: AELA) along with its wholly-owned subsidiary Zentaris GmbH, announced
today that results of the recently completed Phase I trial evaluating
Perifosine, the Company's novel, first-in-class, oral AKT inhibitor in
combination with radiotherapy in patients with unresectable locally advanced
tumors will be presented at the upcoming American Society of Clinical Oncology
(ASCO) Annual Meeting. The meeting will take place in New Orleans, LA, June 5
through 8, 2004. The lead investigator for the trial, Dr. Marcel Verheij, from
the Department of Radiation of the Netherlands Cancer Institute of Amsterdam,
will present the results.

The Phase I results to be presented at ASCO will form the basis for a Phase II
trial evaluating Perifosine in combination with radiotherapy in patients
selected for specific tumor types. Zentaris plans to evaluate Perifosine in
combination with radiotherapy as a treatment for multiple types of cancer
through the ongoing collaboration with the Netherlands Cancer Institute of
Amsterdam.

The ongoing clinical development of Perifosine in North America includes nine
Phase II trials in six cancer types that are being conducted through
collaboration between Zentaris GmbH, Keryx Biopharmaceuticals Inc. (Nasdaq:
KERX) and the United States National Cancer Institute (NCI). AEterna, through
Zentaris GmbH, holds ex-North America rights to Perifosine. To date, five Phase
I trials have been conducted on Perifosine, including the trial to be
highlighted at ASCO. In the four preceding trials, use of Perifosine as a single
agent in a total of 94 patients provided initial, encouraging evidence of
anti-tumor activity. Namely, investigators observed two partial responses (>50%
reduction) in patients with sarcoma and sixteen stable disease in patients with
breast, prostate, pancreatic and other forms of cancer.

Initial data from the Phase I trial undertaken by Dr. Verheij to evaluate the
safety and tolerability, as well as to determine the maximum tolerated dose of
Perifosine in the combination therapy regimen were reported in 2003 at the
Second International Conference on Translational Research and Preclinical
Strategies in Radiation Oncology (Lugano, Switzerland). Initial data in 7
patients with non-small cell lung cancer (NSCLC) and bladder cancer, who
received Perifosine doses ranging from 50 to 100 mg/day concurrently with
standard doses of radiotherapy, demonstrated acceptable tolerability. In
addition, the combination regimen was not associated with bone marrow toxicity,
an often treatment-limiting side effect associated with many cancer therapies
currently on the market. The trial was continued with the goal to define the
highest dose of Perifosine that is well tolerated in the combination regimen.

ABOUT AETERNA LABORATORIES

FORWARD-LOOKING STATEMENTS

-30-
CONTACTS:

U.S. INVESTOR RELATIONS EUROPE
Lippert/Heilshorn & Associates Zentaris GmbH
Kim Golodetz Matthias Seeber
(212) 838-3777 phone: + 49 69 42 602 3425
kgolodetz@lhai.com fax: + 49 69 42 602 3444
matthias.seeber@zentaris.de

[AETERNA LOGO]

PRESS RELEASE
FOR IMMEDIATE RELEASE

AETERNA SUBSIDIARY ZENTARIS ANNOUNCES INITIATION OF DOSE
RANGING STUDY FOR A NOVEL ORAL AGENT THAT STIMULATES GROWTH
HORMONE SECRETION

QUEBEC CITY, CANADA, APRIL 21, 2004 - AEterna Laboratories Inc. (TSX: AEL;
NASDAQ: AELA), along with its wholly-owned subsidiary Zentaris GmbH, announced
today the initiation of a dose ranging study for its EP-1572 Growth Hormone
Secretagogue (GHS), a novel, orally-available peptidomimetic agent which can
directly stimulate growth hormone secretion from the pituitary gland. The study
will evaluate the safety and pharmacokinetics/pharmacodynamics of the compound
administered by oral route and its initiation triggers an undisclosed milestone
payment to AEterna from its development partner Ardana Bioscience. Potential
indications for EP-1572 include treatment of growth hormone deficiency disorders
in adults and children (short stature), frailty of the elderly, as well as
metabolic complications associated with critical illnesses, such as
AIDS-associated cachexia, cancer, and trauma.

"We believe there is a critical need for effective oral therapies addressing
disorders associated with reduced secretion of growth hormone and are very
encouraged by EP-1572's potential in this respect as demonstrated by studies to
date. Productive partnerships are an important component of a successful
commercialization strategy, and the initiation of these studies signifies yet
another achievement in our ongoing collaboration with Ardana Bioscience," said
Prof. Jurgen Engel, Chairman & Managing Director of Zentaris GmbH, Executive
Vice President R&D and Chief Operating Officer at AEterna.

"We are very excited to advance this promising compound into dose ranging
studies as we believe it has the potential to represent a major new advance in
the treatment of growth hormone deficiency disorders," commented Dr Maureen
Lindsay, Ardana Chief Operating Officer. "Ardana has a rich and broad
development portfolio comprising products near launch, in clinical development
and preclinical evaluation. We look forward to the results of this study before
the end of 2004."

ABOUT EP-1572 GROWTH HORMONE SECRETAGOGUE (GSH)

EP-1572 is a novel, orally-available peptidomimetic agent which can directly
stimulate growth hormone secretion (growth hormone secretagogue) from the
pituitary gland through binding to GHS receptors without the involvement of
growth hormone release hormone (GHRH) or somatostatin. It is also one of the
first compounds of this class to enter clinical development. Growth hormone
plays a critical role in stimulating body growth and development, including
development of bone structure and muscle mass, as well as controls protein
synthesis and fat breakdown, leading to increased lean body mass.

Potential indications for EP-1572 include treatment of growth hormone deficiency
disorders in adults and children (short stature), frailty of the elderly, as
well as metabolic complications

associated with critical illnesses, such as AIDS-associated cachexia, cancer,
and trauma. The current standard of therapy for most of these disorders is
hormone replacement therapy through sometimes daily administration of growth
hormone which, unlike EP-1572, cannot be taken orally and has to be injected.
Furthermore, whereas current therapy relies on administration of growth hormone
produced through recombinant DNA technology, EP-1572 administration has the
potential to induce pulsed production of natural growth hormone. Potential sales
of effective, orally-administered compounds addressing growth hormone
deficiency-associated disorders in all age groups, including frailty of the
elderly (worldwide prevalence estimated at 43.5 million people by 2012),
currently underserved by existing therapies can have blockbuster (several
billion Euros) potential.

ABOUT AETERNA LABORATORIES

AEterna Laboratories Inc., along with its wholly-owned subsidiary Zentaris GmbH,
is a biopharmaceutical company with an extensive product portfolio, including
two marketed products and 14 other product candidates under development in
oncology, endocrinology and infectious diseases. Cetrorelix (Cetrotide(R)) is
sold in the U.S., Europe and several other countries to the in vitro
fertilization market, and is in Phase II clinical trials for endometriosis,
uterus myoma and enlarged prostate (BPH). Miltefosine (Impavido(R)) is sold for
black fever and has successfully completed a Phase III trial in parasitic skin
disease. Neovastat(R) is in a Phase III trial for non-small cell lung cancer.
Perifosine, the first orally-active AKT inhibitor, is in Phase II trials for
multiple cancers. Several other clinical programs are underway with various
potential development candidates, supported by a worldwide network of scientific
and marketing partnerships. Furthermore, AEterna benefits from a discovery
platform of 100,000 molecules, which is generating promising new compounds.

ABOUT ARDANA BIOSCIENCE

Ardana Bioscience is a specialty pharmaceutical company focused on reproductive
health. It aims to become a leading source of clinical and commercial innovation
in the $20 billion human reproductive health market, which is growing at 9% per
annum. In addition to the androgen replacement therapy which will be launched in
the UK in 2004, Ardana has a rich development portfolio including Chronodyne(R)
(terbutaline) for endometriosis-related infertility (being developed in
collaboration with Columbia Laboratories (NASDAQ CBRX) and GnRH analogs
`Teverelix' and `Leuprorelin' for a wide variety of reproductive indications.
Ardana's therapeutic interests encompass androgen replacement, infertility,
sexual dysfunction and obstetrics. www.ardana.co.uk

FORWARD-LOOKING STATEMENTS

pursue R&D projects, the successful and timely completion of clinical studies,
the ability of the Company to take advantage of business opportunities in the
pharmaceutical industry, uncertainties related to the regulatory process and
general changes in economic conditions. Investors should consult the Company's
quarterly and annual filings with the Canadian and U.S. securities commissions
for additional information on risks and uncertainties relating to the
forward-looking statements. Investors are cautioned not to rely on these
forward-looking statements. The Company does not undertake to update these
forward-looking statements.

-30-

CONTACTS:

U.S. INVESTOR RELATIONS EUROPE
Lippert/Heilshorn & Associates Zentaris GmbH
Kim Golodetz Dr. Mathias Pietras
(212) 838-3777 phone: + 49 69 42 602 3423
kgolodetz@lhai.com mathias.pietras@zentaris.de

[AETERNA LOGO]

PRESS RELEASE
FOR IMMEDIATE RELEASE

AETERNA/ZENTARIS AND SOLVAY REPORT HEADLINE POSITIVE DATA
FROM SIX PHASE II TRIALS OF CETRORELIX IN THREE INDICATIONS:
ENDOMETRIOSIS, UTERINE MYOMAS AND
BENIGN PROSTATIC HYPERPLASIA

Clinical Phase II data in endometriosis and in pre-surgical treatment of
uterine myomas to be presented at the 18th World Congress of the
International Federation of Fertility Societies (IFFS) on May 23-28, 2004

ALL AMOUNTS ARE IN CANADIAN DOLLARS, UNLESS INDICATED OTHERWISE

QUEBEC CITY, CANADA, APRIL 29, 2004 - AEterna Laboratories Inc. (TSX: AEL;
NASDAQ: AELA), along with its wholly-owned subsidiary Zentaris GmbH, today
announced statistically significant positive results from a recently completed
Phase II clinical program designed to evaluate cetrorelix, a luteinizing hormone
releasing hormone (LHRH) antagonist, in three different indications:
endometriosis, pre-surgical treatment of uterine myomas and benign prostatic
hyperplasia (BPH), that can benefit from a targeted and controlled decrease in
sex hormones, including estrogen and testosterone. The positive results of six
Phase II trials, which also demonstrated good tolerability in all indications,
will form the basis for further development of cetrorelix in different
indications through collaboration with Solvay Pharmaceuticals, the Company's
worldwide (ex-Japan) exclusive development and marketing partner for cetrorelix
for the above indications.

Detailed Phase II data with new depot formulation of cetrorelix in endometriosis
and in pre-surgical treatment of uterine myomas will be presented during the
18th World Congress of the International Federation of Fertility Societies
(IFFS), which will be held in Montreal, Canada, on May 23-28, 2004.

"The striking results we have seen with cetrorelix in these trials, particularly
in endometriosis, deliver on the promise of LHRH antagonists and are the
culmination of many years of research and development efforts which originated
from Dr. Schally's Nobel-Prize winning research into LHRH and its antagonists,"
said Prof. Jurgen Engel, Chairman & Managing Director of Zentaris GmbH,
Executive Vice President R&D and Chief Operating Officer at AEterna. "Unlike
other LHRH antagonists currently on the market or in clinical development,
cetrorelix has a unique profile, avoiding total reduction (castration) of the
different hormone levels. In addition, modulation of the epidermal growth factor
receptor (EGFr) levels by cetrorelix has been shown in myoma cells, an effect
that could be broadly applicable outside the cancer area."

"We are very excited about these positive Phase II results and are preparing a
development plan in the different indications to expedite the registration of
cetrorelix. We are especially enthusiastic about endometriosis for which no good
treatment is currently available," stated Dr. Werner Cautreels, Solvay
Pharmaceuticals' Global Head of R&D.

According to Gilles Gagnon, President and Chief Executive Officer at AEterna,
"cetrorelix, together with perifosine, form the cornerstone of our pipeline and,
as such, we are very excited about the prospect of seeing cetrorelix enter
pivotal trials in major markets. We look forward to further leveraging the depth
and breadth of the product pipeline that we obtained through the acquisition of
Zentaris to continue to deliver benefits to patients and value to our
shareholders."

ENDOMETRIOSIS

The placebo-controlled study demonstrated that cetrorelix use was associated
with a rapid and durable therapeutic response, namely improvement of
endometriosis-related symptoms, such as pelvic pain, extending up to several
months following only two intramuscular injections of cetrorelix with a one
month interval.

The Company believes that the clinical data indicate that cetrorelix, unlike
currently used treatments for endometriosis such as LHRH agonists, is suitable
for long-term use as an intermittent treatment for endometriosis.

Endometriosis is the growth of the endometrium, or the inside lining of the
uterus, outside of the uterus and is dependent upon the level of estrogen.
Endometriosis affects approximately 10% to 20% of women of child-bearing age,
and there is still a high medical need for new treatments. The total market size
in 2003 was estimated to be around US$800 million.

UTERINE MYOMAS

Placebo-controlled trials have demonstrated that subcutaneous administrations of
cetrorelix lead to the reduction of myoma/uterine volume within one month only.

Uterine myoma is a benign tumor of the uterus which is composed of muscle
tissue. The growth of uterine myomas depends on the level of estrogen.
Approximately 15% of all women of child-bearing age have uterine myomas. It is
estimated that more than US$150 million are spent annually on drug treatment.

BENIGN PROSTATIC HYPERPLASIA (BPH)

Two placebo-controlled Phase II trials were conducted in BPH. As early as one
month following initiation of therapy, data from both trials demonstrated a
dose-dependent improvement of clinical symptoms, including IPSS (International
Prostate Symptom Score) and maximum uroflow in the cetrorelix treatment group,
in comparison with the placebo group, and the positive effect lasted three
months without additional administration of cetrorelix. Furthermore, the use of
cetrorelix was associated with a slight reduction of prostate size and did not
have an adverse influence on sexual activity or libido.

Benign prostate hyperplasia is characterized by an abnormal, but not malignant,
testosterone-mediated growth of prostate tissue. BPH is estimated to affect
approximately 33 million men over 60 years of age. In 2004, the amount spent on
drug treatment is expected to be around US$1.8 billion.

ABOUT SOLVAY PHARMACEUTICALS

Solvay Pharmaceuticals is a member of the Solvay group of pharmaceutical and
chemical companies. Operating globally with corporate offices in Europe, the
U.S. and Japan, and sales and marketing companies in more than 45 countries,
Solvay Pharmaceuticals employs 7,500 people worldwide. It has research and
development activities concentrated onto carefully selected clinical targets in
the fields of psychiatry, gastroenterology, cardiology and gynaecology. The
Solvay Group employs more than 30,000 people in three sectors of activity:
pharmaceuticals, chemicals and plastics. For further information on Solvay,
please visit the websites www.solvay.com or www.solvaypharmaceuticals.com.
-------------- -----------------------------

ABOUT AETERNA LABORATORIES

FORWARD-LOOKING STATEMENTS

-30-

CONTACTS:

U.S. INVESTOR RELATIONS EUROPE
Lippert/Heilshorn & Associates Zentaris GmbH
Kim Golodetz Mathias Pietras
(212) 838-3777 phone: + 49 69 42 602 3423
kgolodetz@lhai.com mathias.pietras@zentaris.de

[AETERNA LOGO]

PRESS RELEASE
FOR IMMEDIATE RELEASE

AETERNA LABORATORIES REPORTS FIRST QUARTER 2004 FINANCIAL AND OPERATING RESULTS

O AETERNA CONSOLIDATED RESULTS
- REVENUES INCREASED 43% TO $58.4 MILLION
- OPERATING INCOME OF $1.6 MILLION
- NET LOSS PER SHARE REDUCED BY HALF TO $0.06 PER SHARE

O SUBSIDIARY ATRIUM SALES INCREASED 62% TO $45.8 MILLION AND NET EARNINGS
INCREASED 119% TO $3.6 MILLION

ALL AMOUNTS ARE IN CANADIAN DOLLARS

QUEBEC CITY, CANADA, MAY 4, 2004 - AEterna Laboratories Inc. (TSX: AEL; Nasdaq:
AELA) today reported financial results for the first quarter ended March 31,
2004. Revenues for the first quarter 2004 were $58.4 million, an increase of 43%
compared with $40.8 million for the same period in 2003. R&D expenses net of tax
credits and grants decreased from $10.9 million in the first quarter of 2003 to
$8.0 million in the first quarter of 2004, reflecting the realignment of the
clinical development program initiated in December 2003, including the
refocusing of the pipeline on perifosine and cetrorelix.

Operating income was $1.6 million for the first quarter of 2004, compared with
an operating loss of $1.3 million for the same period in 2003, primarily
reflecting strong revenue growth of 62% from the majority-owned subsidiary
Atrium. The net loss for the first quarter 2004 was $2.6 million, or $0.06 per
share, a decrease of nearly 50% compared with a net loss of $4.9 million or
$0.12 a share for the same period in 2003.

Commenting on the Company's first quarter results, Gilles Gagnon, AEterna's
President and Chief Executive Officer, said, "We are very pleased by the
financial results and strategic achievements we've had in the first quarter of
2004. The significant increase in revenues was driven by strong performances
from all our sectors of activity. On the strategic front, we continued to
advance and expand our rich product portfolio. We entered into development and
marketing alliances with Roche for Impavido(R) and with Solvay Pharmaceuticals
for our orally-available LHRH antagonist peptidomimetic. We also had an exciting
development last week, with the announcement of positive results from six Phase
II trials on cetrorelix in three indications: uterus myoma, endometriosis and
benign prostatic hyperplasia. Our partner Solvay Pharmaceuticals is already
planning for initiation of registration studies on cetrorelix. We believe these
accomplishments continue to reflect the breadth and depth of our pipeline as
well as the value of our international network of current and potential
partners, which are two key

components of our long-term growth strategy."

Dennis Turpin, AEterna's Vice President and CFO, added, "The Company's financial
position remains solid, with over $52 million in cash and short-term
investments, combined with the continued strong financial performance of both
Atrium and Zentaris."

ATRIUM CONSOLIDATED FIRST QUARTER RESULTS

First quarter 2004 revenues for Atrium, AEterna's majority-owned subsidiary,
were $45.8 million, an increase of 62% compared with $28.3 million in revenues
for the comparable period in 2003. Operating income was $6.1 million during the
quarter, compared with $3.5 million for the same period in 2003, representing a
72% increase. Net earnings increased 119% to $3.6 million, compared with $1.6
million for the same period in 2003. The increase reflects the combination of
internal growth as well as growth driven by acquisition of
Chimiray/Interchemical and Pure Encapsulations Inc., completed in August 2003
and March 2004, respectively.

FIRST QUARTER AND YEAR-TO-DATE 2004 HIGHLIGHTS

o ATRIUM ACQUISITION OF PURE ENCAPSULATIONS INC. - Atrium acquired Pure
Encapsulations Inc., a US-based company specializing in the
development, manufacturing and marketing of nutritional supplements to
a network of some 36,000 physicians and other healthcare
professionals, for $50 million. Pure Encapsulations Inc. had 2003
revenue of nearly $25 million.

o PARTNERSHIP WITH ROCHE FOR IMPAVIDO(R) - Agreement for the marketing,
in Brazil, of Impavido(R) (miltefosine), the first oral treatment for
leishmaniasis, a parasitic disease prevalent in tropical countries
that affects over 12 million people worldwide.

o PARTNERSHIP WITH SOLVAY FOR ORAL LHRH ANTAGONIST - Agreement for the
development of a novel, orally-bioavailable luteinizing
hormone-releasing hormone (LHRH) antagonist peptidomimetic for
non-malignant indications, including endometriosis, uterine myoma and
benign prostate hyperplasia (HPB), as well as breast and prostate
cancer. Upon signing, AEterna received a $5 million payment from
Solvay.

o POSITIVE RESULTS FOR ZEN-014 - Disclosure of positive preclinical
results with ZEN-014, a novel tubulin inhibitor, at the annual
American Association for Cancer Research (AACR). ZEN-014 represents a
new class of antiangiogenic compounds that may have significant
potential as potent anticancer agents.

o INITIATION OF DOSE RANGING STUDY WITH ARDANA FOR EP-1572 - Initiation
of a dose ranging study for this novel, orally-available
peptidomimetic agent which could be used, among different indications,
for the treatment of growth hormone deficiency disorders. AEterna
received an undisclosed milestone payment from its development
partner, Ardana Bioscience.

o EXPANDED PARTNERSHIP WITH ARDANA FOR TEVERELIX - Ardana acquired full
global rights and was assigned the intellectual property relating to
teverelix and the underlying microcrystalline suspension technology.
In return, Zentaris received a substantial payment at signature, fixed
annual guaranteed payments until 2006, as well as potential future
income on sales of teverelix.

o POSITIVE PHASE II RESULTS FOR CETRORELIX - Announcement of positive
results with cetrorelix (LHRH antagonist) in six Phase II trials in
endometriosis, pre-surgical treatment of uterine myomas and benign
prostatic hyperplasia (BPH). Solvay plans to initiate pivotal program
with cetrotrelix.

CONFERENCE CALL INFORMATION

Management will be hosting a conference call for the investment community at
10:00 a.m. Eastern Time today, Tuesday, May 4, to discuss first quarter
financial and operating results.

To participate in the live conference call by telephone, please dial
514-807-8791, 416-640-4127 or 800-814-4890. Individuals interested in listening
to the conference call via the Internet may do so by visiting www.aeterna.com. A
replay will be available on the Company's Web site for 30 days.

ABOUT AETERNA LABORATORIES

AEterna Laboratories Inc., along with its wholly-owned subsidiary Zentaris GmbH,
is a biopharmaceutical company with an extensive product portfolio, including
two marketed products and 14 other product candidates under development in
oncology, endocrinology and infectious diseases. Cetrorelix (Cetrotide(R)) is
sold in the U.S., Europe and several other countries to the in vitro
fertilization market, and has positively completed six Phase II clinical trials
for endometriosis, uterus myoma and enlarged prostate (BPH). Miltefosine
(Impavido(R)) is sold for black fever and has successfully completed a Phase III
trial in parasitic skin disease. Neovastat(R) is in a Phase III trial for
non-small cell lung cancer. Perifosine, the first orally-active AKT inhibitor,
is in Phase II trials for multiple cancers. Several other clinical programs are
underway with various potential development candidates, supported by a worldwide
network of scientific and marketing partnerships. Furthermore, AEterna benefits
from a discovery platform of 100,000 molecules, which is generating promising
new compounds.

FORWARD-LOOKING STATEMENTS

-30-

CONTACTS:

U.S. INVESTOR RELATIONS EUROPE
Lippert/Heilshorn & Associates Zentaris GmbH
Kim Golodetz Mathias Pietras
(212) 838-3777 phone: + 49 69 42 602 3423
kgolodetz@lhai.com mathias.pietras@zentaris.de

Attachment: Financial summary

AETERNA LABORATORIES INC. (TSX: AEL ; NASDAQ: AELA)
FINANCIAL SUMMARY
(in thousands of Canadian dollars, except share and per share data)

THREE MONTHS ENDED
MARCH 31,
---------------------------------------
CONSOLIDATED RESULTS 2004 2003
Unaudited $ $
----------------------------------------------------------------------------------------------------------

REVENUES 58,449 40,813
------------- --------------
OPERATING EXPENSES
Cost of sales 37,128 23,220
Selling, general and administrative 9,621 5,495
R&D costs, net of tax credits and grants 7,953 10,916
Depreciation and amortization 2,163 2,503
------------- --------------
56,865 42,134
------------- --------------
Operating income (loss) 1,584 (1,321)
Interest income 494 937
Interest and financial expenses (1,637) (793)
Foreign exchange gain (loss) 417 (387)
------------- --------------
INCOME (LOSS) BEFORE THE FOLLOWING ITEMS 858 (1,564)
Current income taxes (2,424) (632)
Future income taxes 784 (1,869)
Non-controlling interest (1,768) (825)
------------- --------------
NET LOSS FOR THE PERIOD (2,550) (4,890)
------------- --------------
------------- --------------
Basic and diluted net loss per share (0.06) (0.12)
------------- --------------
------------- --------------
Weighted average number of shares 45,402,892 40,693,527
Issued and outstanding shares 45,440,242 40,693,527

MARCH 31, DECEMBER 31,
---------------------------------------
CONSOLIDATED BALANCE SHEETS 2004 2003
$ $
----------------------------------------------------------------------------------------------------------

Cash and short-term investments 51,989 64,367
Other current assets 87,035 70,278
------------- --------------
139,024 134,645
Long-term assets 203,821 161,134
------------- --------------
Total assets 342,845 295,779
------------- --------------
------------- --------------
Current liabilities 73,575 61,442
Deferred revenues 13,600 10,563
Convertible term loans and long-term debt 69,773 35,052
Other long-term liabilities 31,542 32,649
Non-controlling interest 31,039 29,952
------------- --------------
219,529 169,658
Shareholders' equity 123,316 126,121
------------- --------------
Total liabilities and shareholders' equity 342,845 295,779
------------- --------------
------------- --------------

[AETERNA LOGO]

PRESS RELEASE
FOR IMMEDIATE RELEASE

AETERNA LABORATORIES TO HOLD INVESTOR AND ANALYST DAY ON
MAY 17, 2004 IN NEW YORK CITY

THE MEETING WILL BE HELD AT THE ST. REGIS HOTEL AND WILL START AT 1:15 P.M. EDT

QUEBEC CITY, CANADA, MAY 11, 2004 - AEterna Laboratories Inc. (TSX: AEL; Nasdaq:
AELA), along with its wholly-owned subsidiary Zentaris GmbH, today announced
plans to host an Investor and Analyst Day on Monday, May 17, 2004 from 1:15 p.m.
- 4:00 p.m. EDT at the St. Regis Hotel in New York City. The event will include
presentations from the Company management, who will provide a corporate overview
and an update on the Company's broad product portfolio focused on oncology and
endocrine therapy. In addition, several leading outside physician experts have
been invited to speak about the opportunities for products currently under
development, with a particular emphasis on perifosine, the Company's novel,
first-in-class, oral AKT inhibitor for the treatment of cancer, and cetrorelix,
an LHRH antagonist which recently completed a broad Phase II program in
endometriosis, uterine myomas and benign prostatic hyperplasia.

An audio webcast of the Investor and Analyst Day presentations will be available
live and may be accessed by visiting the Investors section of AEterna's website,
www.aeterna.com. A replay will also be available at the same site.

ABOUT AETERNA LABORATORIES

AEterna Laboratories Inc., along with its wholly-owned subsidiary Zentaris GmbH,
is a biopharmaceutical company focused in oncology and endocrine therapy. Its
extensive portfolio, from drug discovery to marketed products, includes
perifosine, an orally-active AKT inhibitor in several Phase II trials for
multiple cancers, and cetrorelix, an LHRH antagonist already marketed for in
vitro fertilization under the brand name Cetrotide(R), and also in advanced
clinical development for the treatment of uterine myoma, endometriosis and
enlarged prostate (BPH).

FORWARD-LOOKING STATEMENTS

-30-

CONTACTS:

AETERNA LABORATORIES
MEDIA RELATIONS OR TO REGISTER FOR INVESTOR
AND ANALYST DAY EVENT: INVESTOR RELATIONS
Paul Burroughs Jacques Raymond
(418) 652-8525 ext. 406 (418) 652-8525 ext. 360
paul.burroughs@aeterna.com jacques.raymond@aeterna.com

U.S. INVESTOR RELATIONS EUROPE
Lippert/Heilshorn & Associates Zentaris GmbH
Kim Golodetz Dr. Mathias Pietras
(212) 838-3777 phone: + 49 69 42 602 3423
kgolodetz@lhai.com mathias.pietras@zentaris.de

[AETERNA LOGO]

PRESS RELEASE
FOR IMMEDIATE RELEASE

AETERNA/ZENTARIS TO PRESENT DETAILED POSITIVE PHASE II DATA ON
CETRORELIX AND NEW PRECLINICAL DATA ON PERIFOSINE DURING
INVESTOR AND ANALYST DAY IN NEW YORK CITY

HEADLINE POSITIVE PHASE II DATA ON CETRORELIX WERE REPORTED ON APRIL 29, 2004,
WITH ADDITIONAL DETAILED PHASE II DATA IN ENDOMETRIOSIS AND PRE-SURGICAL
TREATMENT OF UTERINE MYOMAS TO BE PRESENTED AT THE 18TH WORLD CONGRESS OF THE
INTERNATIONAL FEDERATION OF FERTILITY SOCIETIES (IFFS) ON MAY 23-28, 2004

QUEBEC CITY, CANADA, MAY 17, 2004 - AEterna Laboratories Inc. (TSX: AEL; Nasdaq:
AELA), along with its wholly-owned subsidiary Zentaris GmbH, today announced
that it will present detailed positive Phase II data on cetrorelix, a
luteinizing hormone-releasing hormone (LHRH) antagonist, in endometriosis and
benign prostatic hyperplasia (BPH) during the Investor and Analyst Day being
held in New York City today. These results will form the basis for further
development of cetrorelix through collaboration with Solvay Pharmaceuticals, the
Company's worldwide (ex-Japan) exclusive development and marketing partner. In
addition, AEterna/Zentaris will present new encouraging preclinical data on
perifosine, the Company's novel, first-in-class, oral AKT inhibitor, in
combination with radiation therapy, supporting the ongoing clinical development
of perifosine in combination with radiotherapy as a potential treatment for
multiple types of cancer. AEterna/Zentaris plans to initiate Phase II trials of
perifosine in combination with radiotherapy, through the ongoing collaboration
with the Netherlands Cancer Institute of Amsterdam, after presenting Phase I
results at the American Society of Clinical Oncology (ASCO) Annual Meeting in
June 2004.

CETRORELIX IN ENDOMETRIOSIS

A total of three Phase II trials, of which one was double-blind and
placebo-controlled, were conducted to evaluate different dosage regimens and
formulations of cetrorelix in patients with endometriosis. Highly encouraging
results were seen in the double-blind, placebo-controlled trial in two groups of
25 patients with endometriosis who received either placebo or depot formulation
of cetrorelix by two intramuscular injections with a one-month interval.
Assessment of pain (including dysmenorrhea, dyspareunia, and chronic pelvic
pain), one of the main endometriosis-related symptoms, up to 24 weeks after the
first injection, demonstrated that cetrorelix use was associated with a highly
statistically significant (p= less than 0.001) improvement of pain score.
Furthermore, therapeutic response associated with cetrorelix use was both rapid
in onset (within four weeks) and durable, extending up to five months following
cessation of cetrorelix administration. Importantly, clinical benefit seen with
the use of cetrorelix was associated with only a slight and transient
suppression of serum estrogen levels. Cetrorelix was well tolerated and was not
associated with side effects, such as hormonal withdrawal symptoms seen during
menopause.

The Company believes that Phase II data from this placebo-controlled trial,
backed up by data from the two open-label, non-placebo controlled Phase II
trials, indicate that cetrorelix, unlike currently used treatments for
endometriosis such as LHRH agonists, is suitable for long-term use as an
intermittent treatment for endometriosis.

CETRORELIX IN BPH

Two placebo-controlled Phase II trials were conducted to evaluate the efficacy
of cetrorelix, including durability of therapeutic response associated with
cetrorelix use during a four-month post-injection follow-up period, in 250
patients with BPH.

In the first Phase II trial, patients with BPH received a single intramuscular
injection of 30 mg or 60 mg of the same depot formulation of cetrorelix as that
used in the placebo-controlled trial for endometriosis discussed above. In the
second Phase II trial, patients received four weekly subcutaneous injections of
5 mg or 10 mg of a different formulation of cetrorelix. In both studies, the
clinical effects were followed for four months after the last injection.

As early as one month following initiation of therapy, data from both trials
demonstrated a dose-dependent improvement of clinical symptoms, including IPSS
(International Prostate Symptom Score) and maximum uroflow in the cetrorelix
treatment group in comparison with the placebo group. Importantly, the
therapeutic response lasted three months following cessation of cetrorelix
administration. In addition, the use of cetrorelix was associated with a slight
reduction of prostate size. The clinical benefits seen with the use of
cetrorelix were associated with a transient decrease of serum testosterone which
never reached the castration level and thus did not have an adverse influence on
sexual activity or libido.

NEW PRECLINICAL DATA ON PERIFOSINE IN COMBINATION WITH RADIOTHERAPY

AEterna/Zentaris will also present new encouraging preclinical (IN VIVO) data on
perifosine, the Company's novel, first-in-class, oral AKT inhibitor in
combination with radiation therapy.

Mouse xenograft tumor models were used to evaluate the anti-tumor activity of
oral administration of perifosine or radiation alone as compared to perifosine
in combination with radiation. Whereas the use of either treatment modality
alone only delayed tumor growth, the combination regimen with both treatments
led to complete tumor regression.

The Company believes that these IN VIVO results support the ongoing clinical
development of perifosine in combination with radiotherapy as a potential
treatment for multiple types of cancer. Phase I data on perifosine in
combination with radiation therapy will be presented at the American Society of
Clinical Oncology (ASCO) Annual Meeting in June 2004.

AEterna/Zentaris plans to initiate Phase II trials of perifosine in combination
with radiotherapy, through the ongoing collaboration with the Netherlands Cancer
Institute of Amsterdam.

ADVANCEMENT OF TEVERELIX IN PHASE IIa TRIALS

Earlier today, Ardana Bioscience, the worldwide partner of AEterna/Zentaris for
the development and marketing of teverelix, a LHRH antagonist, has separately
announced the initiation of a Phase IIa trial for patients with prostate cancer,
as well as the planned initiation of a new Phase IIa trial in patients with BPH
to be started later this week. The advancement of teverelix into Phase IIa
follows a recently completed Phase I trial which helped establish the dosage
regimens necessary to achieve different levels of testosterone suppression.

AUDIO WEBCAST

An audio webcast of the Investor and Analyst Day presentations is available live
and may be accessed by visiting the Investors section of AEterna's website,
www.aeterna.com. A replay will also be available at the same site.

ABOUT AETERNA LABORATORIES

AEterna Laboratories Inc., along with its wholly-owned subsidiary Zentaris GmbH,
is a biopharmaceutical company focused in oncology and endocrine therapy. Its
extensive portfolio, from drug discovery to marketed products, includes
perifosine, an orally-active AKT inhibitor in several Phase II trials for
multiple cancers, and cetrorelix, an LHRH antagonist already marketed for IN
VITRO fertilization under the brand name Cetrotide(R), and also in advanced
clinical development for the treatment of uterine myoma, endometriosis and
enlarged prostate (BPH).

FORWARD-LOOKING STATEMENTS

-30-

CONTACTS:

AETERNA LABORATORIES
MEDIA RELATIONS INVESTOR RELATIONS
Paul Burroughs Jacques Raymond
(418) 652-8525 ext. 406 (418) 652-8525 ext. 360
paul.burroughs@aeterna.com jacques.raymond@aeterna.com

U.S. INVESTOR RELATIONS EUROPE
Lippert/Heilshorn & Associates Zentaris GmbH
Kim Golodetz Dr. Mathias Pietras
(212) 838-3777 phone: + 49 69 42 602 3423
kgolodetz@lhai.com mathias.pietras@zentaris.de

[AETERNA LOGO]

PRESS RELEASE
FOR IMMEDIATE RELEASE

AETERNA LABORATORIES ADDED TO NASDAQ BIOTECH INDEX

QUEBEC CITY, CANADA, MAY 17, 2004 - AEterna Laboratories Inc. (TSX: AEL; Nasdaq:
AELA) today announced that it has been selected to be added to the NASDAQ
Biotechnology Index (NBI) effective on Monday, May 24, 2004. All securities in
the Index are listed on the NASDAQ National Market and meet minimum
requirements, including market value and average daily share volume.

Launched in 1993, the NASDAQ Biotechnology Index consists of pharmaceutical and
biotechnology companies as classified by the FTSE(TM) Global Classification
System. The Index is ranked on a semi-annual basis in May and in November and
serves as the basis for the Shares NASDAQ Biotechnology Index Fund(SM) (AMEX:
IBB). For more information about the NASDAQ Biotechnology Index, including
eligibility criteria, visit www.nasdaq.com.
--------------

ABOUT AETERNA LABORATORIES

AEterna Laboratories Inc., along with its wholly-owned subsidiary Zentaris GmbH,
is a biopharmaceutical company focused in oncology and endocrine therapy. Its
extensive portfolio, from drug discovery to marketed products, includes
perifosine, an orally-active AKT inhibitor in several Phase II trials for
multiple cancers, and cetrorelix, an LHRH antagonist already marketed for IN
VITRO fertilization under the brand name Cetrotide(R), and also in advanced
clinical development for the treatment of uterine myoma, endometriosis and
enlarged prostate (BPH).

FORWARD-LOOKING STATEMENTS

-30-

CONTACTS:

AETERNA LABORATORIES
MEDIA RELATIONS INVESTOR RELATIONS
Paul Burroughs Jacques Raymond
(418) 652-8525 ext. 406 (418) 652-8525 ext. 360
paul.burroughs@aeterna.com jacques.raymond@aeterna.com

U.S. INVESTOR RELATIONS EUROPE
Lippert/Heilshorn & Associates Zentaris GmbH
Kim Golodetz Dr. Mathias Pietras
(212) 838-3777 phone: + 49 69 42 602 3423
kgolodetz@lhai.com mathias.pietras@zentaris.de

[AETERNA LOGO]

PRESS RELEASE
FOR IMMEDIATE RELEASE

AETERNA TO PRESENT AT UBS GLOBAL SPECIALTY PHARMACEUTICALS
CONFERENCE MAY 24 AND ANNUAL SHAREHOLDER MEETING TO BE HELD MAY 26

QUEBEC CITY, CANADA, MAY 19, 2004 - AEterna Laboratories Inc. (TSX: AEL; Nasdaq:
AELA) announced today that Gilles Gagnon, President and Chief Executive Officer
of the Company will present a corporate update at the UBS Global Specialty
Pharmaceuticals Conference at 8:30 a.m. ET on Monday, May 24, 2004, which will
be held at the Grand Hyatt Hotel in New York City.

To access the audio webcast of the UBS presentation, go to:

http://event.streamx.us/event/default.asp?event=ubs20040524 and find the
Conferences link in the middle of the page. Follow the link for Webcast under
the Global Specialty Pharmaceuticals Conference heading. You can also access
this audio webcast on AEterna's website at www.aeterna.com. Replays will be
---------------
available the following business day for 30 days after the presentation at both
web site addresses.

AEterna management also announced that its annual shareholder meeting will be
held Wednesday, May 26 2004 at 10:30 a.m. in the Ovale room at the Ritz-Carlton
Hotel in Montreal.

ABOUT AETERNA LABORATORIES INC.

AEterna Laboratories Inc., along with its wholly-owned subsidiary Zentaris GmbH,
is a biopharmaceutical company focused in oncology and endocrine therapy. Its
extensive portfolio, from drug discovery to marketed products, includes
perifosine, an orally-active AKT inhibitor in several Phase II trials for
multiple cancers, and cetrorelix, an LHRH antagonist already marketed for IN
VITRO fertilization under the brand name Cetrotide(R), and also in advanced
clinical development for the treatment of uterine myoma, endometriosis and
enlarged prostate (BPH).

FORWARD-LOOKING STATEMENTS

-30-

CONTACTS:

MEDIA RELATIONS INVESTOR RELATIONS
Paul Burroughs Jacques Raymond
(418) 652-8525 ext. 406 (418) 652-8525 ext. 360
paul.burroughs@aeterna.com jacques.raymond@aeterna.com

U.S. INVESTOR RELATIONS EUROPE
Lippert/Heilshorn & Associates Zentaris GmbH
Kim Golodetz Matthias Seeber
(212) 838-3777 +49 69 42602 3425
kgolodetz@lhai.com matthias.seeber@zentaris.de

[AETERNA LOGO]

PRESS RELEASE
FOR IMMEDIATE RELEASE

AETERNA/ZENTARIS TO PRESENT TODAY ADDITIONAL DETAILED
POSITIVE PHASE II DATA ON CETRORELIX IN GYNECOLOGICAL
INDICATIONS AT THE 18TH WORLD CONGRESS OF THE INTERNATIONAL
FEDERATION OF FERTILITY SOCIETIES (IFFS)

QUEBEC CITY, CANADA, MAY 25, 2004 - AEterna Laboratories Inc. (TSX: AEL; Nasdaq:
AELA), along with its wholly-owned subsidiary Zentaris GmbH, announced today
that the Company will present further detailed positive Phase II data on
cetrorelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, in
endometriosis and pre-surgical treatment of uterine myomas at today's session of
the World Congress of the International Federation of Fertility Societies (IFFS)
being held in Montreal. These results combined with those previously announced,
will form the basis for further development of cetrorelix by Solvay
Pharmaceuticals, the Company's worldwide (ex-Japan) exclusive development and
marketing partner for this product candidate. In addition, this will trigger an
undisclosed milestone payment by Solvay.

CETRORELIX IN ENDOMETRIOSIS

A total of three Phase II trials, of which one was double-blind and
placebo-controlled, were conducted to evaluate different dosage regimens (weekly
and monthly) and formulations (for intramuscular and subcutaneous
administration) of cetrorelix in 150 patients with endometriosis.

Highly encouraging results, including highly statistically significant (p=
less than 0.001) improvement of pain score, from the double-blind,
placebo-controlled trial in two groups of 25 patients with endometriosis who
received either placebo or depot formulation of cetrorelix by two
intramuscular injections with a one-month interval were presented at the
Company's Investor and Analyst Day held in New York City on May 17, 2004.

New data from an open-label Phase II trial evaluating three dosage regimens of
weekly subcutaneous injections of cetrorelix in patients with endometriosis will
be presented today at the IFFS meeting. Data from this trial demonstrated that
the therapeutic response, namely a significant decrease in endometriosis-related
symptoms, associated with the use of all three dosage regimens of cetrorelix was
both rapid in onset (within four weeks after initiation of therapy) as well as
durable, extending for at least two months following cessation of cetrorelix
administration. Measurements of serum estrogen demonstrated that all dosage
regimens of cetrorelix led to the suppression of the cycle-dependent hormone
fluctuations, without leading to the pattern of hormonal withdrawal symptoms
seen during menopause. Details on clinical responses according to dosage
regimens will be presented during the Congress of the IFFS.

The Company believes that highly statistically significant Phase II data from
this open-label trial, backed up by data from two other Phase II trials of which
one was double-blind and placebo-controlled, support the long-term use of
cetrorelix as an intermittent treatment for endometriosis, unlike currently used
treatments for endometriosis such as LHRH agonists which are only suitable for
short-term use.

CETRORELIX IN PRE-SURGICAL TREATMENT OF UTERINE MYOMAS

Positive results from a double-blind, placebo-controlled, multi-center Phase II
trial evaluating the subcutaneous formulation of cetrorelix, administered weekly
for four weeks, as a pre-surgical treatment in 109 women with uterine myomas
will also be presented today at the IFFS. Headline results from this trial were
announced on April 29, 2004. In addition to evaluating the safety and
tolerability of different doses of the new formulation, the trial also evaluated
whether cetrorelix use could lead to the reduction of myoma and uterine volumes
within a shorter treatment period than that normally required for LHRH agonists.
Data from this trial demonstrated that cetrorelix use led to a reduction of
myoma and uterine volumes after a one-month treatment period, which is
significantly shorter than the 2-6 month treatment period typically required for
LHRH agonists. The best response rate was obtained at a dose of 10 mg cetrorelix
per week. Cetrorelix use did not lead to chemical castration.

Uterine myoma is a benign tumor of the uterus composed of muscle tissue. The
growth of uterine myomas depends on the level of estrogen. Approximately 15% of
all women of child-bearing age have uterine myomas. It is estimated that
annually more than US$150 million are spent on drug treatment.

ABOUT AETERNA LABORATORIES

AEterna Laboratories Inc., along with its wholly-owned subsidiary Zentaris GmbH,
is a biopharmaceutical company focused in oncology and endocrine therapy. Its
extensive portfolio, from drug discovery to marketed products, includes
perifosine, an orally-active AKT inhibitor in several Phase II trials for
multiple cancers, and cetrorelix, an LHRH antagonist already marketed for IN
VITRO fertilization under the brand name Cetrotide(R), and also in advanced
clinical development for the treatment of uterine myoma, endometriosis and
benign prostatic hyperplasia (BPH).

FORWARD-LOOKING STATEMENTS

-30-

CONTACTS:

AETERNA LABORATORIES
MEDIA RELATIONS INVESTOR RELATIONS
Paul Burroughs Jacques Raymond
(418) 652-8525 ext. 406 (418) 652-8525 ext. 360
paul.burroughs@aeterna.com jacques.raymond@aeterna.com

U.S. INVESTOR RELATIONS EUROPE
Lippert/Heilshorn & Associates Zentaris GmbH
Kim Golodetz Dr. Mathias Pietras
(212) 838-3777 phone: + 49 69 42 602 3423
kgolodetz@lhai.com mathias.pietras@zentaris.de

AETERNA ZENTARIS INC.
1405 du Parc-Technologique Blvd.
Quebec (Quebec) Canada G1P 4P5 Quebec
T 418 652-8525 F 418 652-0881 AEterna Zentaris Frankfurt

PRESS RELEASE
For immediate release

AETERNA LABORATORIES HOLDS 2004 ANNUAL SHAREHOLDER MEETING
AND ANNOUNCES COMPANY NAME CHANGE TO AETERNA ZENTARIS

ALL AMOUNTS ARE IN CANADIAN DOLLARS

MONTREAL, QUEBEC, MAY 26, 2004 - At the Annual Shareholder Meeting today, Gilles
Gagnon, President and Chief Executive Officer of AEterna Laboratories Inc. (TSX:
AEL, NASDAQ: AELA) unveiled the Company's new corporate name, AEterna Zentaris
Inc., as approved by shareholders. In conjunction with the name change, the
Company's TSX and NASDAQ ticker symbols will be changed in the near future to
AEZ and AEZS, respectively. As of today, its new corporate website address is
www.aeternazentaris.com.
-----------------------

2003 AND YEAR-TO-DATE 2004 HIGHLIGHTS

During the Annual Shareholder Meeting, Gilles Gagnon discussed the Company's
achievements in 2003 and year-to-date 2004. "The year 2003 was exciting but
challenging where we had to successfully integrate our two companies on one hand
while on the other hand, Neovastat failed in reaching the primary end point in
its phase III renal cell carcinoma trial. Today, I am very pleased with the
turnaround of our Company with the focus that has shifted on two compounds
coming from the Zentaris portfolio, perifosine and cetrorelix. These products
now form the basis for the establishment of our company as a significant player
in oncology and endocrinology. In that respect, the new identity AEterna
Zentaris better reflects our Company's evolution. Our corporate vision is to
become an international biopharmaceutical company. We are confident that at
AEterna Zentaris, we are well positioned to continue to build value for our
shareholders by pursuing a strategic growth plan based on aggressive advancement
of our clinical development programs and the continued growth of our subsidiary
Atrium," said Gilles Gagnon.

Dr. Jurgen Engel, Executive Vice President Global R&D and Chief Operating
Officer of AEterna Zentaris further commented that in 2004, the Company plans to
focus its efforts on the advancement of its clinical pipeline, with a particular
emphasis on perifosine and cetrorelix, but also on bringing additional
innovative preclinical products to the clinical stage. "Considering the scope
and breadth of our product portfolio and the strength of our international
partnership network, we are confident that AEterna Zentaris is well positioned
to pursue its growth in 2004 and beyond," concluded Dr. Engel.

OUTLOOK 2004

The Company's specific goals for 2004 include:

o Present Phase I data on perifosine in combination with radiotherapy at
ASCO, June 04
o Report preliminary Phase II data on perifosine from multiple North American
trials 2H 04
o Initiate Phase II combination trials with perifosine
o Develop new perifosine analogs

o Advance one or more preclinical compounds into Phase I trials
o Initiate pivotal program on cetrorelix with Solvay
o Receive marketing approval for Cetrotide(R) (cetrorelix) in Japan for in
VITRO fertilization

FINANCIAL POSITION

"With our marketed products, strategic partners, innovative pipeline and our
subsidiary Atrium, we believe we can offer our investors a unique value
proposition. Our cash position now stands at nearly $52 million and we expect to
become cash-flow positive in 2004," commented Dennis Turpin, Vice President and
Chief Financial Officer.

APPOINTMENT TO MANAGEMENT TEAM

In addition to his current function as Medical Director at AEterna Zentaris'
subsidiary in Germany, Dr. Manfred Peukert, MD was appointed Vice President,
Medical Affairs. Dr. Peukert is a seasoned executive who spent more than 30
years in the pharmaceutical industry. He joined Asta Medica in 1976 where he
held several executive positions up to Global Head of Medical Research
activities. He has a broad experience in many therapeutic areas with a specific
expertise in the management of medical research projects in oncology and
endocrinology.

SHAREHOLDER MEETING HIGHLIGHTS

CORPORATE NAME CHANGE
o AEterna Laboratories Inc. changes its name to AEterna Zentaris Inc.

MARKETED PRODUCTS
o Cetrotide(R) (cetrorelix) - Signed long-term deal with Serono for IN VITRO
fertilization
o Impavido(R) (miltefosine) - Launched in India for visceral leishmaniasis
(black fever)

CLINICAL
o Cetrorelix - Completed six positive Phase II trials in three indications:
endometriosis, uterine myomas and benign prostatic hyperplasia (BPH)
o Perifosine - Advanced to nine Phase II trials (NCI) in multiple cancers
o D-63153 - Progressed in Phase II trial for prostate cancer
o Teverelix - Initiation of Phase IIa trials in prostate cancer and BPH

PRECLINICAL
o LHRH peptidomimetic (oral) - Partnered with Solvay
o GH secretagogue - Advanced to Phase I trial
o AN series cytotoxic conjugates - Progressed in preclinical studies
o Tubulin inhibitors - Progressed in preclinical studies

SHAREHOLDER RIGHTS PLAN
o The proposed shareholder rights plan has been approved by shareholders

SUBSIDIARY ATRIUM
o Atrium sales of $120.3 million and operating income of $14.4 million in
2003
o Strong internal and acquisition driven growth
o Chimiray/Interchemical (France)
o Siricie S.A. (France)
o Pure Encapsulations Inc. (United States)

ABOUT AETERNA ZENTARIS INC.

AEterna Zentaris Inc. is a biopharmaceutical company focused in oncology and
endocrine therapy. Its extensive portfolio, from drug discovery to marketed
products, includes perifosine, an orally-active AKT inhibitor in several Phase
II trials for multiple cancers, and cetrorelix, an LHRH antagonist already
marketed for IN VITRO fertilization under the brand name Cetrotide(R), and also
in advanced clinical development for the treatment of uterine myoma,
endometriosis and benign prostatic hyperplasia (BPH).

AEterna Zentaris owns 100% of Zentaris GmbH in Germany. It also owns 62% of
Atrium Biotechnologies Inc., which develops, distributes and markets active
ingredients, speciality fine chemicals, cosmetic and nutritional products for
the cosmetics, chemical, pharmaceutical and nutritional industries.

News releases and additional information about AEterna Zentaris are available on
its new Web site www.aeternazentaris.com.
-----------------------

FORWARD-LOOKING STATEMENTS

-30-

CONTACTS:

MEDIA RELATIONS INVESTOR RELATIONS
Paul Burroughs Jacques Raymond
(418) 652-8525 ext. 406 (418) 652-8525 ext. 360
paul.burroughs@aeternazentaris.com jacques.raymond@aeternazentaris.com

U.S. INVESTOR RELATIONS EUROPE
Lippert/Heilshorn & Associates Matthias Seeber
Kim Golodetz +49 69 42602 3425
(212) 838-3777 matthias.seeber@zentaris.de
kgolodetz@lhai.com

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.

AETERNA LABORATORIES INC.

DATE: JULY 6, 2004 By: /s/ Mario Paradis
------------------- --------------------------------------------
Mario Paradis
Senior Director, Finance and Corporate Secretary